top of page
Mental-health-1920.jpg

Introducing 428Pharma.

Developing the world's first treatment to prevent relapse in depression

Our Mission

  • After treatment of the first episode of depression, ~50% of all patients will relapse

  • This risk increases for every subsequent episode:

    • 70% and 90% after a second and third episode respectively

  • After a second relapse patients are defined as treatment resistant (TRD)​​

    • 30% of TRD patients attempt suicide in their lifetime

    • Suicide death rate among persons aged 10–24 increased 56% (2007-2017)

  • Prevention of relapse can prevent patients becoming treatment resistant and reduce their suicide risk

  • There are currently no treatments that reduce relapse in MDD

Our Product

Escitalopram LAI (Long Acting Injectable)

We have a formulation of the worlds first LAI for prevention of relapse in MDD - potential time to market 2028

 

  • First depot injection for SSRI for a vast depression market estimated at $15.8Bn in 2025

  • 505(b)(2) truncated development with LOE 2046.  PK only approval pathway with FDA

  • Opportunity to out-license end of phase I

Misty Field_edited.jpg
bottom of page